Join Growin Stock Community!

Biogen inc.BIIB.US Overview

US StockHealthcare
(No presentation for BIIB)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

BIIB AI Insights

BIIB Overall Performance

BIIB AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BIIB Recent Performance

-2.76%

Biogen inc.

-3.61%

Avg of Sector

-2.16%

S&P500

BIIB PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

BIIB Key Information

BIIB Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

BIIB Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Price of BIIB

BIIB FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

BIIB Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
8.81
PE Ratio (TTM)
21.82
Forward PE
11.79
PS Ratio (TTM)
2.85
PB Ratio
1.51
Price-to-FCF
13.29
METRIC
VALUE
vs. INDUSTRY
Gross Margin
75.69%
Net Margin
13.07%
Revenue Growth (YoY)
2.22%
Profit Growth (YoY)
1.64%
3-Year Revenue Growth
-3.59%
3-Year Profit Growth
-3.30%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
8.81
PE Ratio (TTM)
21.82
Forward PE
11.79
PS Ratio (TTM)
2.85
PB Ratio
1.51
Price-to-FCF
13.29
Gross Margin
75.69%
Net Margin
13.07%
Revenue Growth (YoY)
2.22%
Profit Growth (YoY)
1.64%
3-Year Revenue Growth
-3.59%
3-Year Profit Growth
-3.30%

  • When is BIIB's latest earnings report released?

    The most recent financial report for Biogen inc. (BIIB) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BIIB's short-term business performance and financial health. For the latest updates on BIIB's earnings releases, visit this page regularly.

  • Where does BIIB fall in the P/E River chart?

    According to historical valuation range analysis, Biogen inc. (BIIB)'s current price-to-earnings (P/E) ratio is 22.84, placing it in the Reasonable zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of BIIB?

    According to the latest financial report, Biogen inc. (BIIB) reported an Operating Profit of -56M with an Operating Margin of -2.46% this period, representing a decline of 119.21% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is BIIB's revenue growth?

    In the latest financial report, Biogen inc. (BIIB) announced revenue of 2.28B, with a Year-Over-Year growth rate of -7.14%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does BIIB have?

    At the end of the period, Biogen inc. (BIIB) held Total Cash and Cash Equivalents of 3.01B, accounting for 0.1 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does BIIB go with three margins increasing?

    In the latest report, Biogen inc. (BIIB) did not achieve the “three margins increasing” benchmark, with a gross margin of 78.3%%, operating margin of -2.46%%, and net margin of -2.1%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess BIIB's profit trajectory and future growth potential.

  • Is BIIB's EPS continuing to grow?

    According to the past four quarterly reports, Biogen inc. (BIIB)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.33. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of BIIB?

    Biogen inc. (BIIB)'s Free Cash Flow (FCF) for the period is 451.7M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 34.97% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of BIIB?

    The latest valuation data shows Biogen inc. (BIIB) has a Price-To-Earnings (PE) ratio of 22.84 and a Price/Earnings-To-Growth (PEG) ratio of 1.21. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.